Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$5.10
-1.5%
$4.52
$1.80
$20.83
$26.66M-0.79116,028 shs64,133 shs
Elutia Inc. stock logo
ELUT
Elutia
$2.04
+0.5%
$1.96
$1.61
$5.12
$83.46M0.8825,923 shs15,286 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.12
-1.4%
$2.18
$1.82
$3.09
$87.82M1.6167,113 shs61,152 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58
+8.2%
$1.40
$1.10
$16.10
$89.62M1.421.11 million shs1.48 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
-1.54%-7.27%+17.51%+18.06%+1,344.35%
Elutia Inc. stock logo
ELUT
Elutia
+0.49%+6.25%-5.56%0.00%-44.11%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-1.40%-1.85%-1.85%-8.62%-16.86%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+8.22%+0.64%+31.67%-6.51%-88.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cingulate Inc. stock logo
CING
Cingulate
3.0257 of 5 stars
3.55.00.00.02.50.80.6
Elutia Inc. stock logo
ELUT
Elutia
3.4514 of 5 stars
3.55.00.00.01.93.30.6
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.7783 of 5 stars
0.03.00.00.02.30.80.6
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
3.6375 of 5 stars
3.03.00.04.70.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
3.00
Buy$26.00409.80% Upside
Elutia Inc. stock logo
ELUT
Elutia
3.00
Buy$8.00292.16% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.00
Hold$13.31742.56% Upside

Current Analyst Ratings Breakdown

Latest CING, PLRX, ELUT, and ORMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $61.00
5/19/2025
Cingulate Inc. stock logo
CING
Cingulate
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/9/2025
Elutia Inc. stock logo
ELUT
Elutia
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$2.32 per shareN/A
Elutia Inc. stock logo
ELUT
Elutia
$24.38M3.44N/AN/A($1.31) per share-1.56
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$1.34M64.63N/AN/A$3.61 per share0.59
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M61.39N/AN/A$5.00 per share0.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)
Elutia Inc. stock logo
ELUT
Elutia
-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%8/6/2025 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$210.30M-$3.61N/AN/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)

Latest CING, PLRX, ELUT, and ORMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025N/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.01N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Cingulate Inc. stock logo
CING
Cingulate
-$0.82N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.62N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03-$0.19-$0.16-$0.19N/A$2.00 million
5/8/2025Q1 2025
Cingulate Inc. stock logo
CING
Cingulate
-$1.00-$1.04-$0.04-$1.04N/AN/A
5/8/2025Q1 2025
Elutia Inc. stock logo
ELUT
Elutia
-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Elutia Inc. stock logo
ELUT
Elutia
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
0.16
1.87
1.87
Elutia Inc. stock logo
ELUT
Elutia
N/A
0.81
0.70
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
23.94
23.94
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/A
11.03
11.03

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Elutia Inc. stock logo
ELUT
Elutia
74.03%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
5.27%
Elutia Inc. stock logo
ELUT
Elutia
27.60%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
13.70%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
8.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
205.15 million4.88 millionNot Optionable
Elutia Inc. stock logo
ELUT
Elutia
18041.12 million29.77 millionNot Optionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.85 million35.25 millionOptionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.39 million56.48 millionOptionable

Recent News About These Companies

Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics announces workforce reduction

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cingulate stock logo

Cingulate NASDAQ:CING

$5.10 -0.08 (-1.54%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.69 -0.41 (-8.12%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Elutia stock logo

Elutia NASDAQ:ELUT

$2.04 +0.01 (+0.49%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.04 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.12 -0.03 (-1.40%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.11 -0.01 (-0.47%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.58 +0.12 (+8.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.62 +0.03 (+2.22%)
As of 08/1/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.